Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility?

ABSTRACT:

Background

Phosphorylated tau 217 (p-tau217) has emerged as a leading blood-based biomarker for Alzheimer disease (AD). While typically measured in plasma, serum is a widely used matrix in clinical laboratories, yet few p-tau217 assays have been validated for serum. Evaluating serum p-tau217 performance is essential for expanding its use in clinical and research settings, particularly for cohorts with only serum samples available.

Methods

We quantified p-tau217 in plasma and serum from individuals within the AD continuum (n = 100; mean age 72.5 ± 5.0 years; 54% female) using 6 assays across 4 platforms. Spearman correlation, Passing-Bablok regression, and receiver operating characteristics analysis were used to assess intermatrix agreement and diagnostic performance. Specifi

SUBMITTER: Benedet AL 

PROVIDER: S-EPMC12865796 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature